A randomised, placebo-controlled study of RIPK1 inhibitor GSK2982772 in patients with active ulcerative colitis

A randomised, placebo-controlled study of RIPK1 inhibitor GSK2982772 in patients with active ulcerative colitis

Objective Tumour necrosis factor signalling via the receptor-interacting protein kinase 1 (RIPK1) pathway regulates colonic inflammation suggesting that RIPK1 inhibition may be a potential therapeutic target in ulcerative colitis (UC). This phase IIa, randomised, double-blind experimental medicine s...

Full description

Saved in:
Bibliographic Details
Main Authors: Nicola Scott, Kurt Brown, Paul Peter Tak, Kathy Weisel, Scott Berger, Susanne Wang, Marcy Powell, Matthijs Broer, Clarissa Watts, Debra J Tompson, Susan W Burriss, Simon Hawkins, Kathy Abbott-Banner
Format: Article
Language:English
Published: BMJ Publishing Group 2021-10-01
Series:BMJ Open Gastroenterology
Online Access:https://bmjopengastro.bmj.com/content/8/1/e000680.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://bmjopengastro.bmj.com/content/8/1/e000680.full

Similar Items